Y0N

2-[6-(4-acetylpiperazin-1-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]-N-[(3,4-dichlorophenyl)methyl]acetamide

Created:	2023-06-09
Last modified:	2024-12-18

Find Related PDB Entry
1 entries where Y0N is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	57
Chiral Atom Count	0
Bond Count	60
Aromatic Bond Count	12

2D diagram of Y0N

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	2-[6-(4-acetylpiperazin-1-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]-N-[(3,4-dichlorophenyl)methyl]acetamide
Systematic Name (OpenEye OEToolkits)	~{N}-[(3,4-dichlorophenyl)methyl]-2-[6-(4-ethanoylpiperazin-1-yl)-2,4-bis(oxidanylidene)-1~{H}-quinazolin-3-yl]ethanamide
Formula	C₂₃ H₂₃ Cl₂ N₅ O₄
Molecular Weight	504.366
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	O=C(C)N1CCN(CC1)c1cc2C(=O)N(CC(=O)NCc3ccc(Cl)c(Cl)c3)C(=O)Nc2cc1
SMILES	CACTVS	3.385	CC(=O)N1CCN(CC1)c2ccc3NC(=O)N(CC(=O)NCc4ccc(Cl)c(Cl)c4)C(=O)c3c2
SMILES	OpenEye OEToolkits	2.0.7	CC(=O)N1CCN(CC1)c2ccc3c(c2)C(=O)N(C(=O)N3)CC(=O)NCc4ccc(c(c4)Cl)Cl
Canonical SMILES	CACTVS	3.385	CC(=O)N1CCN(CC1)c2ccc3NC(=O)N(CC(=O)NCc4ccc(Cl)c(Cl)c4)C(=O)c3c2
Canonical SMILES	OpenEye OEToolkits	2.0.7	CC(=O)N1CCN(CC1)c2ccc3c(c2)C(=O)N(C(=O)N3)CC(=O)NCc4ccc(c(c4)Cl)Cl
InChI	InChI	1.06	InChI=1S/C23H23Cl2N5O4/c1-14(31)28-6-8-29(9-7-28)16-3-5-20-17(11-16)22(33)30(23(34)27-20)13-21(32)26-12-15-2-4-18(24)19(25)10-15/h2-5,10-11H,6-9,12-13H2,1H3,(H,26,32)(H,27,34)
InChIKey	InChI	1.06	MLEBKOFCEIQPJZ-UHFFFAOYSA-N

Related Resource References

Resource Name	Reference
PubChem	122603620

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.